X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare VENUS REMEDIES with Elder Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs ELDER PHARMA - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES ELDER PHARMA VENUS REMEDIES/
ELDER PHARMA
 
P/E (TTM) x -836.1 -0.2 - View Chart
P/BV x 0.2 0.1 242.3% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 VENUS REMEDIES   ELDER PHARMA
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-16
ELDER PHARMA
Jun-14
VENUS REMEDIES/
ELDER PHARMA
5-Yr Chart
Click to enlarge
High Rs218380 57.4%   
Low Rs82188 43.7%   
Sales per share (Unadj.) Rs365.6491.2 74.4%  
Earnings per share (Unadj.) Rs1.5-3.2 -46.7%  
Cash flow per share (Unadj.) Rs37.914.4 263.2%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs382.5376.5 101.6%  
Shares outstanding (eoy) m11.4420.54 55.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.40.6 71.0%   
Avg P/E ratio x101.0-89.3 -113.1%  
P/CF ratio (eoy) x4.019.7 20.1%  
Price / Book Value ratio x0.40.8 52.0%  
Dividend payout %00-   
Avg Mkt Cap Rs m1,7175,833 29.4%   
No. of employees `0001.0NA-   
Total wages/salary Rs m3242,179 14.9%   
Avg. sales/employee Rs Th4,100.7NM-  
Avg. wages/employee Rs Th318.0NM-  
Avg. net profit/employee Rs Th16.7NM-  
INCOME DATA
Net Sales Rs m4,18310,089 41.5%  
Other income Rs m20257 7.8%   
Total revenues Rs m4,20310,346 40.6%   
Gross profit Rs m812-792 -102.5%  
Depreciation Rs m417361 115.4%   
Interest Rs m3802,756 13.8%   
Profit before tax Rs m35-3,653 -1.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m03,713 0.0%   
Tax Rs m18125 14.5%   
Profit after tax Rs m17-65 -26.0%  
Gross profit margin %19.4-7.8 -247.2%  
Effective tax rate %51.6-3.4 -1,505.1%   
Net profit margin %0.4-0.6 -62.7%  
BALANCE SHEET DATA
Current assets Rs m2,7719,240 30.0%   
Current liabilities Rs m1,9319,998 19.3%   
Net working cap to sales %20.1-7.5 -267.2%  
Current ratio x1.40.9 155.2%  
Inventory Days Days12546 270.0%  
Debtors Days Days5460 89.7%  
Net fixed assets Rs m5,32810,124 52.6%   
Share capital Rs m114206 55.6%   
"Free" reserves Rs m4,1775,582 74.8%   
Net worth Rs m4,3767,734 56.6%   
Long term debt Rs m1,9114,889 39.1%   
Total assets Rs m8,42822,882 36.8%  
Interest coverage x1.1-0.3 -335.8%   
Debt to equity ratio x0.40.6 69.1%  
Sales to assets ratio x0.50.4 112.6%   
Return on assets %4.711.8 40.0%  
Return on equity %0.4-0.8 -46.0%  
Return on capital %6.622.3 29.6%  
Exports to sales %03.0 0.0%   
Imports to sales %20.50.4 4,803.7%   
Exports (fob) Rs mNA307 0.0%   
Imports (cif) Rs m85843 1,991.5%   
Fx inflow Rs m0307 0.0%   
Fx outflow Rs m858125 685.0%   
Net fx Rs m-858181 -473.4%   
CASH FLOW
From Operations Rs m46911,754 4.0%  
From Investments Rs m29-561 -5.2%  
From Financial Activity Rs m-464-6,762 6.9%  
Net Cashflow Rs m354,432 0.8%  

Share Holding

Indian Promoters % 32.9 39.6 83.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.2 7.5 2.4%  
FIIs % 0.6 16.8 3.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 36.1 183.9%  
Shareholders   20,121 16,479 122.1%  
Pledged promoter(s) holding % 36.4 77.6 46.9%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   SUVEN LIFE  SHASUN PHARMA  PFIZER  FDC LTD.  ORCHID PHARMA LTD  

Compare VENUS REMEDIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex, Nifty at Record Close Yet Again; IT & Realty Stocks Rally(Closing)

Indian share markets extended rally in the final hour of the trade, hitting fresh record highs while the Bank nifty touched 27,000 level for the first time. At the closing bell.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Jan 22, 2018 (Close)

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES 8-QTR ANALYSIS

COMPARE VENUS REMEDIES WITH

MARKET STATS